<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707209</url>
  </required_header>
  <id_info>
    <org_study_id>1000072947</org_study_id>
    <nct_id>NCT04707209</nct_id>
  </id_info>
  <brief_title>Sirolimus for Retinal Astrocytic Hamartoma</brief_title>
  <official_title>Intravitreal Injection of Sirolimus in the Treatment of Aggressive Retinal Astrocytic Hamartoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal&#xD;
      astrocytic hamartomas (RAH) of both eyes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinal astrocytic hamartomas (RAH) are benign tumors of glial cells arising from astrocytes&#xD;
      in the nerve-fiber layer of the retina. They are often associated with tuberous sclerosis&#xD;
      complex (TSC) and, more rarely, neurofibromatosis type 1 (NF1). RAH may be caused by&#xD;
      dysregulated tumor suppressors genes TSC1 or TSC2, which play a role in cell cycle regulation&#xD;
      in retinal astrocytes via the PDGF-signalling pathway. Downregulation of TSC1 or TSC2 can&#xD;
      result in hyperactivation of mTOR. Sirolimus is an inhibitor of mTOR, therefore inhibiting&#xD;
      cell growth and proliferation of astrocytes. Systemic mTOR inhibitors (sirolimus and&#xD;
      everolimus) have shown impressive reduction in the size of RAH in animal models and many&#xD;
      human case series.&#xD;
&#xD;
      This single patient study is investigating the use of concurrent oral and intravitreal&#xD;
      Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes&#xD;
      to improve intraocular response and reduce duration of treatment. The patient has no other&#xD;
      clinical features suggestive of neurofibromatosis and a presumed diagnosis of tuberous&#xD;
      sclerosis is being considered, with only two hypopigmented skin lesions noted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of Retinal Astrocytic Hamartomas compared to baseline</measure>
    <time_frame>14 months</time_frame>
    <description>Measured by ophthalmic imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of retinal exudate compared to baseline</measure>
    <time_frame>14 months</time_frame>
    <description>Measured by ophthalmic imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal detachment progression/regression compared to baseline</measure>
    <time_frame>14 months</time_frame>
    <description>Measured by ophthalmic imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity compared to baseline</measure>
    <time_frame>14 months</time_frame>
    <description>Measured using logMAR virtual activity test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Retinal Astrocytic Hamartoma</condition>
  <arm_group>
    <arm_group_label>Intravitreal Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>An intravitreal injection of 20 ÂµL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.&#xD;
Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.&#xD;
Injections will be repeated every eight weeks. A total of 3-6 injections will be given per eye, over 6-12 months. The current treatment plan is for a maximum of six injections per eye, which may be amended to accommodate more in the future.</description>
    <arm_group_label>Intravitreal Sirolimus</arm_group_label>
    <other_name>DE-109</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Single case diagnosed with multiple retinal astrocytic hamartomas (RAH) of both eyes with&#xD;
        imminent threat to vision.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashwin Mallipatna, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>207403</phone_ext>
    <email>ashwin.mallipatna@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaitlyn Flegg, MSc</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>203287</phone_ext>
    <email>kaitlyn.flegg@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Flegg, MSc</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>203287</phone_ext>
      <email>Kaitlyn.flegg@sickkids.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Ashwin Mallipatna</investigator_full_name>
    <investigator_title>Paediatric Ophthalmologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hamartoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

